Table 2.

Clinical Trial with CTLA4-Ig (Abatacept) in kidney/immunological diseases. Abatacept (marketed as Orencia) is a fusion protien generated with an immunoglobulin fused to the extracellular domain of CTLA4 and capable of stable binding to B7.1/CD80, thus blocking its activation.

Study/Identifier	Purpose	Status/PI
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis NCT00430677	The purpose of this clinical research study is to learn if abatacept treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and steroid as part of this study will control the nephritis despite a protocol-defined steroid taper; the endpoint is "confirmed complete renal response", a composite including stabilization or improvement of renal function, improvement of proteinuria, and improvement of urinary sediment. The safety of this treatment will also be studied	Ongoing Bristol-Myers Squibb
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS) NCT00774852	This study is for people with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself	Ongoing David wofsy,, University of California, San Francisco Betty Diamond, MDFeinstein Institute
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis NCT00468208	Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessele, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG	Ongoing Carol A. Langford, The Cleveland Clinic Peter A. Merkel, Boston University
Abatacept in ANCA Associated Vasculitis (ABAVAS) NCT00482066	The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blined placebo controlled trial	Terminated Alan Salama Imperial College London
Intravenous CTLA4-Ig Treatment in Recent Onset Type 1 Diabetes Mellitus NCT00505375	The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo	Ongoing Tihamer Orban, joslin Diabetes Center
Islet Transplantation Using Abatacept NCT00276250	Islet transplantation in type 1 diabetices with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.	Ongoing Christian P Larsen/Thomas C Pearson Emory University